fishing bait

fishing bait Nico Iamaleava throws 4 TD passes to lead No. 10 Tennessee over UTEP 56-0MahaYuti bulldozer flattens MVA, some strands surviveHow Idaho's oldest water law shapes modern farming fights | Guest commentaryVideo: Joey Chestnut Eats World-Record 21 Pounds of Shrimp Before Big Ten Title Game

Lindsey Graham Warns US Allies Over Netanyahu Warrant: 'Crush Your Economy'

Most Read on Euro Weekly NewsColorado QB Shedeur Sanders escapes injury after questionable low hit - Yahoo Sports

The world approved a bitterly negotiated climate deal Sunday committing wealthy historic polluters to $300 billion annually for poor and vulnerable nations that had demanded far more to confront the crisis of global warming. After two exhaustive weeks of chaotic bargaining and sleepless nights, nearly 200 nations banged through the contentious finance pact in the early hours beneath a sports stadium roof in Azerbaijan. Nations had struggled to reconcile long-standing divisions over climate finance. Sleep-deprived diplomats, huddled in anxious groups, were still revising the final phrasing on the plenary floor before the deal passed. At points, the talks appeared on the brink of collapse, with developing nations storming out of meetings and threatening to walk away should rich nations not cough up more cash. In the end -- despite repeating that no deal is better than a bad deal -- they did not stand in the way of an agreement, despite it falling well short of what they want. The final deal commits developed nations to pay at least $300 billion a year by 2035 to help developed countries green their economies and prepare for worse disasters. That is up from $100 billion now provided by wealthy nations under a commitment set to expire -- and from the $250 billion proposed in a draft Friday. That offer was slammed as offensively low by developing countries, which have demanded at least $500 billion to build resilience against climate change and cut emissions. A number of countries have accused Azerbaijan, an authoritarian oil and gas exporter, of lacking the experience and will to meet the moment, as the planet again sets temperature records and faces rising deadly disasters. Wealthy countries and small island nations have also been concerned by efforts led by Saudi Arabia to water down calls from last year's summit to phase out fossil fuels. The United States and EU have wanted newly wealthy emerging economies like China -- the world's largest emitter -- to chip in. The final draft encouraged developing countries to make contributions on a voluntary basis, reflecting no change for China which already pays climate finance on its own terms. Wealthy nations said it was politically unrealistic to expect more in direct government funding. Donald Trump, a sceptic of both climate change and foreign assistance, returns to the White House in January and a number of other Western countries have seen right-wing backlashes against the green agenda. The deal posits a larger overall target of $1.3 trillion per year to cope with rising temperatures and disasters, but most would come from private sources. bur-np-sct/lth/jj

NoneIn just a few years, women will be in control of more money than ever before. By 2030, women are expected to be in charge of $34 trillion in the United States, about 38 percent of all investable assets, Bloomberg reported on Monday. That’s according to data from McKinsey & Company, which show massive gains from the $7.3 trillion that women controlled just a decade ago. “Women are increasingly becoming the financial heads of households due to inheritance, divorce, or career success, and they’re taking on leadership roles in financial decision-making,” Casey Jorgensen, the head of the Dynasty Institute for Adaptive Leadership at Dynasty Financial Partners, told Bloomberg. The trend isn’t just taking place in the U.S.: In Western Europe, women’s financial holdings are set to increase 45 percent by 2030, up from about 4.6 trillion euros ($4.9 trillion) today, according to McKinsey. Between now and then, those assets are expected to compound at 8.1 percent annually, compared with just 2.7 percent for men. If those numbers hold, women could be close to parity with men by the early part of the next decade. In general, women have become in charge of more and more money over the years. There are now at least 62 female billionaires , holding 11 percent of the $9.9 trillion counted by the Bloomberg Billionaires Index. And ultra-high-net-worth women , with $30 million or more, have increased from 6.5 percent of the UHNW population in 2010 to 11 percent in 2023, according to data from the wealth -management firm Julius Baer shared with Bloomberg. That’s a far cry from just 50 years ago, when women couldn’t even open a credit card or bank account on their own. “There’s a huge economic opportunity for organizations to more readily meet the needs of women,” Beth Viner, a managing director and partner at Boston Consulting Group, told Bloomberg. “Wealth management was designed when mostly men were head of households. It’s worth stepping back to say, ‘Are we meeting women’s needs today?’” Part of those needs deal with philanthropy, as women tend to donate more than men, regardless of age or income level, Bloomberg noted. With more money in their pockets, women are likely to give to charity in increased numbers, spanning categories from social justice to religious organizations. It may be a women’s world, after all.

France celebrated the re-opening of Notre Dame cathedral on Saturday at a special church service that featured a standing ovation for the firefighters who saved the 12th-century landmark from destruction during a 2019 blaze. A two-hour service attended by incoming US president Donald Trump among other world leaders began with the archbishop of Paris knocking on the doors of the cathedral three times. "Notre Dame, model of faith, open your doors to bring together the far-flung children of God in joy," archbishop Laurent Ulrich commanded, banging with a wooden staff crafted from a roof beam that survived the inferno five years ago. Trump could be seen sitting on the front row as guest of honour next to French President Emmanuel Macron, with invitees marvelling at the freshly cleaned walls, new furniture and state-of-the-art lighting installed as part of the overhaul. In a short speech, Macron expressed the "gratitude of the French nation" for the restoration work, achieved at frenzied speed over the last five years. France had "rediscovered what great nations can do -- achieve the impossible", he said. One of the most moving moments came when firefighters in their protective gear walked through the congregation to thunderous applause as the word "Merci" ("Thank you") was beamed on the intricate facade and famous belltowers of the Gothic masterpiece. Small crowds of Parisians and tourists braved wet weather and high winds outside to witness the renaissance of a monument, which came close to collapsing due to the intensity of the inferno that toppled its roof and spire. "I find it really beautiful, even more so now that the spire has been restored," Marie Jean, a 27-year-old dentist from southwest France, told AFP outside. The reconstruction effort cost around 700 million euros ($750 million), financed from donations, with the re-opening achieved within a five-year deadline despite predictions it could take decades. Workers had to overcome problems with lead pollution, the Covid-19 epidemic, and the army general overseeing the project falling to his death while hiking in the Pyrenees last year. Saturday's service featured classical music, the cathedral's choir as well as the "re-awakening" of the 8,000-pipe organ which is considered the voice and soul of the cathedral. A televised public concert planned outside featuring Chinese piano virtuoso Lang Lang and possibly US singer and fashion designer Pharrell Williams had to be pre-recorded on Friday night because of the stormy weather. Held up as an example of French creativity and resilience by Macron, Notre Dame's renaissance so soon after the fire comes at a difficult time for the country. The sense of national accomplishment in restoring a symbol of Paris has been undercut by political turmoil that has left France without a proper government since last week when prime minister Michel Barnier lost a confidence vote. Macron is hoping the re-opening might provide a fleeting sense of national pride and unity -- as the Paris Olympics did in July and August. He scored a major coup by attracting Trump along with around 40 heads of state and government, including Ukrainian leader Volodymyr Zelensky, who was given a round of applause as he entered Notre Dame. Macron hosted three-way talks with Zelensky and Trump at the presidential palace shortly before the ceremony, with future US military support for Ukraine's war effort against Russia's invasion expected to have been discussed. Trump has vowed to end the nearly three-year Ukraine war when he takes office on January 20, sparking fears in Kyiv that he will force Ukraine to make territorial concessions to Russia. "It seems like the world is going a little crazy right now and we will be talking about that," Trump told reporters as he prepared to sit down for talks with Macron. One surprising absentee on Saturday was Pope Francis, the head of the Catholic Church. He sent a message addressed to the French people and weighed into a row about whether the place of worship and tourist attraction should remain free to enter. The "immense" numbers set to visit Notre Dame should be welcomed "generously and free of charge", he said, clearly opposing a proposition from the French culture ministry to charge for entry. The exact cause of the 2019 blaze has never been identified despite a forensic investigation by prosecutors, who believe an accident such as an electrical fault was the most likely reason. On Sunday, the first mass with 170 bishops and more than 100 Paris priests will take place at 10:30 am (0930 GMT), followed by a second service in the evening at 6:30 pm which will be open to the public. adp-sjw/jj

Harry Kane becomes the fastest player to score 50 goals in the Bundesliga

Drake Maye looking forward to facing AFC East opponent twice before season ends

The world approved a bitterly negotiated climate deal Sunday committing wealthy historic polluters to $300 billion annually for poor and vulnerable nations that had demanded far more to confront the crisis of global warming. After two exhaustive weeks of chaotic bargaining and sleepless nights, nearly 200 nations banged through the contentious finance pact in the early hours beneath a sports stadium roof in Azerbaijan. Nations had struggled to reconcile long-standing divisions over climate finance. Sleep-deprived diplomats, huddled in anxious groups, were still revising the final phrasing on the plenary floor before the deal passed. At points, the talks appeared on the brink of collapse, with developing nations storming out of meetings and threatening to walk away should rich nations not cough up more cash. In the end -- despite repeating that no deal is better than a bad deal -- they did not stand in the way of an agreement, despite it falling well short of what they want. The final deal commits developed nations to pay at least $300 billion a year by 2035 to help developed countries green their economies and prepare for worse disasters. That is up from $100 billion now provided by wealthy nations under a commitment set to expire -- and from the $250 billion proposed in a draft Friday. That offer was slammed as offensively low by developing countries, which have demanded at least $500 billion to build resilience against climate change and cut emissions. A number of countries have accused Azerbaijan, an authoritarian oil and gas exporter, of lacking the experience and will to meet the moment, as the planet again sets temperature records and faces rising deadly disasters. Wealthy countries and small island nations have also been concerned by efforts led by Saudi Arabia to water down calls from last year's summit to phase out fossil fuels. The United States and EU have wanted newly wealthy emerging economies like China -- the world's largest emitter -- to chip in. The final draft encouraged developing countries to make contributions on a voluntary basis, reflecting no change for China which already pays climate finance on its own terms. Wealthy nations said it was politically unrealistic to expect more in direct government funding. Donald Trump, a sceptic of both climate change and foreign assistance, returns to the White House in January and a number of other Western countries have seen right-wing backlashes against the green agenda. The deal posits a larger overall target of $1.3 trillion per year to cope with rising temperatures and disasters, but most would come from private sources. bur-np-sct/lth/jjOutokumpu invests in a biocarbon plant in Germany to further reduce its direct emissionsGREENVILLE, S.C. (AP) — Pjay Smith Jr. scored 23 points as Furman beat Princeton 69-63 on Saturday. Smith also added eight rebounds and four steals for the Paladins (9-1). Garrett Hien scored 10 points while going 5 of 10 and 0 of 4 from the free-throw line and added seven rebounds. Nick Anderson shot 3 for 9 from beyond the arc to finish with nine points. The Tigers (7-4) were led by Xaivian Lee, who posted 16 points, seven rebounds and five assists. Princeton also got 13 points and four assists from Dalen Davis. Caden Pierce also had 11 points and four steals. NEXT UP Up next for Furman is a Saturday matchup with South Carolina State at home, and Princeton hosts Monmouth on Tuesday. The Associated Press created this story using technology provided by and data from .ISLAMABAD, (UrduPoint / Pakistan Point News - 23rd Nov, 2024) In a landmark step toward judicial reform, of (CJP) Justice Yahya chaired a pivotal meeting at the ’s Branch Registry the other day. The meeting resolved to form a sub-committee dedicated to reforming prison systems in ( ) and drafting a comprehensive package of reforms, said a press release issued on Saturday. The sub-committee, led by Justice Ijaz Anwar Khan of the , includes retired Justice Qalandar Ali Khan, social worker Ms. Ayesha Bano and members both and , alongside representatives the Inspector General of Prisons and the Law and Justice Commission of (LJCP). This committee will assess prison conditions, address issues of under-trial prisoners, and propose rehabilitative programs like vocational training, mental health support, and to prepare inmates for reintegration into society. These efforts aim to align provincial reforms with a forthcoming National Reform Policy, ensuring a fairer, more humane justice system nationwide. Justice praised the for releasing 1,289 prisoners involved in petty crimes and lauded the bravery of in countering threats. He also emphasized the urgent need to upgrade forensic science facilities to strengthen evidence-based investigations. The meeting, attended by prominent judicial and administrative leaders, including Advocate General Utmankhel and Inspector General Akhtar Hayat Khan, also prayed for victims of a recent tragedy in Kurram. The National Reform Policy aims to establish a rehabilitative, transparent, and constitutionally compliant correctional framework aligned with international standards. This collaborative initiative marks a significant step towards addressing inefficiencies in 's justice system.

France celebrated the re-opening of Notre Dame cathedral on Saturday at a special church service that featured a standing ovation for the firefighters who saved the 12th-century landmark from destruction during a 2019 blaze. A two-hour service attended by incoming US president Donald Trump among other world leaders began with the archbishop of Paris knocking on the doors of the cathedral three times. "Notre Dame, model of faith, open your doors to bring together the far-flung children of God in joy," archbishop Laurent Ulrich commanded, banging with a wooden staff crafted from a roof beam that survived the inferno five years ago. Trump could be seen sitting on the front row as guest of honour next to French President Emmanuel Macron, with invitees marvelling at the freshly cleaned walls, new furniture and state-of-the-art lighting installed as part of the overhaul. In a short speech, Macron expressed the "gratitude of the French nation" for the restoration work, achieved at frenzied speed over the last five years. France had "rediscovered what great nations can do -- achieve the impossible", he said. One of the most moving moments came when firefighters in their protective gear walked through the congregation to thunderous applause as the word "Merci" ("Thank you") was beamed on the intricate facade and famous belltowers of the Gothic masterpiece. Small crowds of Parisians and tourists braved wet weather and high winds outside to witness the renaissance of a monument, which came close to collapsing due to the intensity of the inferno that toppled its roof and spire. "I find it really beautiful, even more so now that the spire has been restored," Marie Jean, a 27-year-old dentist from southwest France, told AFP outside. The reconstruction effort cost around 700 million euros ($750 million), financed from donations, with the re-opening achieved within a five-year deadline despite predictions it could take decades. Workers had to overcome problems with lead pollution, the Covid-19 epidemic, and the army general overseeing the project falling to his death while hiking in the Pyrenees last year. Saturday's service featured classical music, the cathedral's choir as well as the "re-awakening" of the 8,000-pipe organ which is considered the voice and soul of the cathedral. A televised public concert planned outside featuring Chinese piano virtuoso Lang Lang and possibly US singer and fashion designer Pharrell Williams had to be pre-recorded on Friday night because of the stormy weather. Held up as an example of French creativity and resilience by Macron, Notre Dame's renaissance so soon after the fire comes at a difficult time for the country. The sense of national accomplishment in restoring a symbol of Paris has been undercut by political turmoil that has left France without a proper government since last week when prime minister Michel Barnier lost a confidence vote. Macron is hoping the re-opening might provide a fleeting sense of national pride and unity -- as the Paris Olympics did in July and August. He scored a major coup by attracting Trump along with around 40 heads of state and government, including Ukrainian leader Volodymyr Zelensky, who was given a round of applause as he entered Notre Dame. Macron hosted three-way talks with Zelensky and Trump at the presidential palace shortly before the ceremony, with future US military support for Ukraine's war effort against Russia's invasion expected to have been discussed. Trump has vowed to end the nearly three-year Ukraine war when he takes office on January 20, sparking fears in Kyiv that he will force Ukraine to make territorial concessions to Russia. "It seems like the world is going a little crazy right now and we will be talking about that," Trump told reporters as he prepared to sit down for talks with Macron. One surprising absentee on Saturday was Pope Francis, the head of the Catholic Church. He sent a message addressed to the French people and weighed into a row about whether the place of worship and tourist attraction should remain free to enter. The "immense" numbers set to visit Notre Dame should be welcomed "generously and free of charge", he said, clearly opposing a proposition from the French culture ministry to charge for entry. The exact cause of the 2019 blaze has never been identified despite a forensic investigation by prosecutors, who believe an accident such as an electrical fault was the most likely reason. On Sunday, the first mass with 170 bishops and more than 100 Paris priests will take place at 10:30 am (0930 GMT), followed by a second service in the evening at 6:30 pm which will be open to the public. adp-sjw/jjWhat happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-CowboysEllington Credit Prepares for Special Meeting and Issues Mirror Preferred StockViad Corp Announces Mandatory Conversion Date for 5.5% Convertible Series A Preferred Stock

WARSAW, Poland (AP) — Warsaw Mayor Rafał Trzaskowski has been selected by Prime Minister Donald Tusk’s centrist Civic Coalition as its candidate in next year's presidential election, beating out Foreign Minister Radek Sikorski. Tusk announced the decision at a party gathering on Saturday, a day after more than 22,000 party members voted in a primary to select who should run to replace the incumbent, Andrzej Duda. Tusk said Trzaskowski won nearly 75% of the votes, and Sikorski slightly over 25%. Political observers in Poland say Tusk's pro-European Union party has already put itself in a strong position ahead of the presidential election by showing that it had two strong candidates, generating a buzz around them and allowing party members to choose in a democratic process. “We are responsible people, we are responsible for the fate of our homeland today,” Tusk told supporters at the party event. He said it was only the start of what is expected to be a difficult campaign. The primary process distinguishes Tusk's party from its main rival, the national conservative Law and Justice party, known by its acronym PiS, whose candidate will be handpicked by leader Jarosław Kaczyński. The candidate is expected to be announced at a party convention in Krakow on Sunday. “In PiS, one vote matters, while we value every vote, and that’s how we differ,” Trzaskowski told party members in his acceptance speech. “I’m convinced that we’re coming out of this primary stronger, we’re all stronger, and I have a very strong mandate and a lot of energy, determination and courage to beat PiS.” Sikorski congratulated Trzaskowski and promised his support. Trzaskowski has long been considered the obvious candidate for Tusk’s party but was recently challenged by Sikorski, who argued that his experience in security and defense issues made him the better choice at a time of war in neighboring Ukraine and political change in the United States. But party members overwhelmingly stuck with Trzaskowski — and were in a good mood as they gathered over coffee and cookies after cheering the outcome. One, Małgorzata Kobus, told The Associated Press that she voted for Trzaskowski because he has been an excellent mayor, preserving green spaces and historical monuments in the capital. She also appreciates that he is highly educated and fluent in several foreign languages. Another, Hanna Szulczewska, thinks Trzaskowski is well suited to the difficult times in a region near Ukraine. She was persuaded by polls that show Trzaskowski would have a better chance of beating out candidates from other parties. “I am really convinced that he will make a fantastic president,” she said. “And strategically we really need a strong candidate.” Trzaskowski, 52, has been mayor since 2018 and has overseen a rapidly changing city of nearly 2 million people that has absorbed large numbers of Ukrainian refugees. He ran for president in 2020, barely losing to Duda. A first round of the presidential election is due to be held in May, and a possible runoff two weeks later if no candidate gets an outright majority in the first round. President Duda will complete his second five-year term in August 2025 and is prevented by the constitution from running again. It is a priority for Tusk to have an ally win the presidency because it will determine whether he can fulfill his agenda. He is currently unable to complete some of his campaign promises because Duda wields veto power over legislation, but also because of opposition within his own three-party coalition. The Civic Coalition is led by Tusk’s party Civic Platform and also includes smaller parties including the Greens.

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenACCRA, Ghana (AP) — Voting closed Saturday evening in most polling centers throughout Ghana, bringing to an end the presidential and legislative elections poised to be a litmus test for democracy in a region shaken by extremist violence and coups . The capital, Accra, was almost a ghost town for much of the day. Even vibrant Oxford Street, one of the city's commercial hubs, saw little activity on the day that Ghanaians went to the polls to elect a new president and 276 legislators. Some 18.7 million people are registered to vote in the West African country hit by one of the worst economic crises in a generation. However, the two main candidates offer little hope for change for the nation. Early results were expected late on Saturday. The first official results will be released by Tuesday. Ghana used to be a poster child for democracy in the region. At a time when coups threatened democracy in West Africa, Ghana emerged as a beacon of democratic stability with a history of peaceful elections. It had also been an economic powerhouse, priding itself on its development. But in recent years, it has struggled with a profound economic crisis, including surging inflation and a lack of jobs. According to an opinion poll released earlier this year by Afrobarometer, a research group, 82% of Ghanaians feel their country is headed in the wrong direction Although 12 candidates are running for president, Saturday’s election — like others since the return of multiparty politics in 1992 — has emerged as a two-horse race. Vice President Mahamudu Bawumia is the candidate of the ruling New Patriotic Party, or NPP, which has struggled to resolve the economic crisis. He faces off against former President John Dramani Mahama, the leader of the main opposition party National Democratic Congress, or NDC. He was voted out in 2016 after failing to deliver on promises for the economy. Opinion polls point to a potential comeback for Mahama. A local research company, Global InfoAnalytics says he is projected to get 52.2% of the vote, followed by Bawumia, with 41.4%. After voting in the town of Bole in northern Ghana, Mahama praised the smooth election process and expressed confidence in his own victory. “In other elections, it had not been clear," he told reporters. “But (during) this election everyone sees where it is heading.” Bawumia, who voted in his Walewale constituency, also in northern Ghana, also said he believed he had won. “By the grace of God, I’m very hopeful of winning this election," he said. “I think that we have done a lot of work. We have put our message to the people; I think the message has been well received.” The NDC prides itself as a social democratic party, while the ruling NPP tags itself as leaning to the right. But in fact, analysts and voters said, the programs of their presidential candidates do not differ in a significant way. Members of parliament will also be elected Saturday. The ruling NPP party and the main opposition NDC each have 137 members in the 275-member legislature, with one independent member who has been voting mostly along with the ruling party. One more constituency will be added in this election, bringing the number of deputies to 276. In their final campaign rallies Thursday, both candidates made a last push to pitch their political parties as the answer to Ghana’s economic woes. Bawumia, 61, an Oxford-educated economist and former deputy governor of the country’s central bank, promised to build on the outgoing administration’s efforts and stabilize the economy. Mahama, 65, on the other hand, restated his promise to “reset” the country on various fronts. “We need to reset our democracy, governance, economy, finances, agriculture, infrastructure, environment, health sector, and all that we hold dear as a people,” the former president said. Across the the capital, Accra, the mood for the election has been upbeat in posters and billboards with bikers displaying stunts, political rallies on the streets, election jingles and songs blasting from public speakers. But the concern for many is also palpable for the key thing at stake: The country’s ailing economy, which has been challenged on various fronts in recent years. The country defaulted on most of its foreign debt last year as it faced a worsening economic crisis that spiked the price of fuel, food and other essential items. The inflation rate had hit 54% by the end of last year and though it’s been coming down since then, not many Ghanaians can still tell the difference when they go to the market. Ebenezer Kotey Dsane, a 69-year-old driver said he voted for Mahama because “he is a good man” who “set up much infrastructure when he was in office.” “The current regime hasn't done much,” he said, pointing to the La General Hospital in Accra, one of the capital's main medical facilities, pulled down in July 2020 by the current government with a pledge to reconstruct it. “Until today, nothing has happened.” Some chose not to vote at all. Ruth Mensah, 42, an unemployed resident of Nima, a working-class suburb in Accra, said she decided not to cast a ballot. “I don’t see how voting will bring about a change to my life,” she said. Patricia Seyram Hagbevor, 20, a first-time voter and student at Accra Technical University said she wished for a change. She didn't disclose whom she voted for, but said she “hoped for a change for the better that will help develop our future.” The chronic challenge of illegal gold mining — known locally as galamsey — has also been a major issue in the campaign and a source of concern for voters, triggering protests and criticism against the outgoing government. Ghana is Africa’s top gold producer and the world’s sixth largest, but the commodity has been increasingly mined illegally as people become more desperate to find jobs in an economy that has been crumbling. The mining has polluted rivers and other parts of the environment despite government actions to clamp down on the practice. Pronczuk reported from Dakar, Senegal.

SACRAMENTO, Calif. (AP) — California, home to some of the largest technology companies in the world, would be the first U.S. state to require mental health warning labels on social media sites if lawmakers pass a bill introduced Monday. The legislation sponsored by state Attorney General Rob Bonta is necessary to bolster safety for children online, supporters say, but industry officials vow to fight the measure and others like it under the First Amendment. Warning labels for social media gained swift bipartisan support from dozens of attorneys general, including Bonta, after U.S. Surgeon General Vivek Murthy called on Congress to establish the requirements earlier this year, saying social media is a contributing factor in the mental health crisis among young people. “These companies know the harmful impact their products can have on our children, and they refuse to take meaningful steps to make them safer,” Bonta said at a news conference Monday. “Time is up. It’s time we stepped in and demanded change.” State officials haven't provided details on the bill, but Bonta said the warning labels could pop up once weekly. Up to 95% of youth ages 13 to 17 say they use a social media platform, and more than a third say that they use social media “almost constantly,” according to 2022 data from the Pew Research Center. Parents’ concerns prompted Australia to pass the world’s first law banning social media for children under 16 in November. “The promise of social media, although real, has turned into a situation where they’re turning our children’s attention into a commodity,” Assemblymember Rebecca Bauer-Kahan, who authored the California bill, said Monday. “The attention economy is using our children and their well-being to make money for these California companies.” Lawmakers instead should focus on online safety education and mental health resources, not warning label bills that are “constitutionally unsound,” said Todd O’Boyle, a vice president of the tech industry policy group Chamber of Progress. “We strongly suspect that the courts will set them aside as compelled speech,” O’Boyle told The Associated Press. Victoria Hinks' 16-year-old daughter, Alexandra, died by suicide four months ago after being “led down dark rabbit holes” on social media that glamorized eating disorders and self-harm. Hinks said the labels would help protect children from companies that turn a blind eye to the harm caused to children’s mental health when they become addicted to social media platforms. “There's not a bone in my body that doubts social media played a role in leading her to that final, irreversible decision,” Hinks said. “This could be your story." Common Sense Media, a sponsor of the bill, said it plans to lobby for similar proposals in other states. California in the past decade has positioned itself as a leader in regulating and fighting the tech industry to bolster online safety for children. The state was the first in 2022 to bar online platforms from using users’ personal information in ways that could harm children. It was one of the states that sued Meta in 2023 and TikTok in October for deliberately designing addictive features that keep kids hooked on their platforms. Gov. Gavin Newsom, a Democrat, also signed several bills in September to help curb the effects of social media on children, including one to prohibit social media platforms from knowingly providing addictive feeds to children without parental consent and one to limit or ban students from using smartphones on school campus. Federal lawmakers have held hearings on child online safety and legislation is in the works to force companies to take reasonable steps to prevent harm. The legislation has the support of X owner Elon Musk and the President-elect’s son, Donald Trump Jr. Still, the last federal law aimed at protecting children online was enacted in 1998, six years before Facebook’s founding. To remove this article -Delay in deciding mercy plea violates convict's rights: Supreme Court